Immunoglobulin expression levels as biomarker for proteasome inhibitor response
AssigneeOnyx Therapeutics, Inc.
InventorsBrian Tuch, Jeremiah Degenhardt, Andrea Loehr, Kevin Kwei, Christopher J. Kirk
Life of this patent
Estimating the term…
Loading patent…
AssigneeOnyx Therapeutics, Inc.
InventorsBrian Tuch, Jeremiah Degenhardt, Andrea Loehr, Kevin Kwei, Christopher J. Kirk
Estimating the term…
Methods of treating a tumor in a subject and methods of determining a treatment regimen for a subject with a tumor are provided herein. In exemplary aspects, the methods comprise measuring the level of expression of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof. In exemplary aspects, the subject is a subject from which a sample was obtained, wherein the level of immunoglobulin, FCGR2B, a gene listed in Table 4, or a combination thereof, has been measured from the sample. Related kits, computer readable-storage media, systems, and methods implemented by a processor in a computer are further provided.
A method for treating a tumor in a subject, said method comprising (i) determining the subject as responsive to treatment with a proteasome inhibitor by (a) obtaining a sample from the subject, wherein the sample comprises a cell from the tumor, (b) measuring the level of expression of Fc gamma receptor 2B (FCGR2B) in the sample and (c) determining the subject as responsive to treatment with a proteasome inhibitor when the level of expression of FCGR2B of the sample is greater than or equal to an FPKQ cutoff of 75 and (ii) administering to the subject an effective amount of a proteasome inhibitor.
Dependencies are inferred from the claim text.